We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Revealing the “Active DUBome” With DUBprofiler-Cell™


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Revealing the “Active DUBome” With DUBprofiler-Cell™"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ubiquigent has announced the launch of a new service as part of its Drug Discovery Screening Platform – DUBprofiler-Cell™.

DUBprofiler-Cell™ is designed to support the development of novel deubiquitylase (DUB) enzyme inhibitors by revealing the “active DUBome” in a given cell-line or tissue (e.g. non-diseased and diseased), and by reporting the target engagement of test compounds to that “active DUBome”.

The DUBprofiler-Cell™ assay utilizes activity-based probes to capture active DUBs (i.e. DUBs with reactive catalytic site cysteine residues) within a cell-line or tissue. By pre-incubating lysates or live cells with test compounds, the assay can be used to evaluate target engagement by compounds. This approach allows proteins to be assayed under physiological conditions (e.g. use of a relevant cell line or tissue; proteins at endogenous expression levels and with a natural assembly and modification status) and is a complementary method to build upon data from in vitro DUBprofiler™ service utilizing recombinant DUB enzymes.

Proof of concept validation of the assay has been demonstrated using potent covalent or non-covalent mechanisms of action selective inhibitors of USP7 or USP30; targets of significant interest in oncology and neurodegeneration, respectively. Other DUBs can be targeted using DUBprofiler-Cell™ as required.

DUBprofiler-Cell™ marks Ubiquigent’s first assay service that incorporates the use of mass spectrometry (MS) to enable an unbiased readout of cellular compound-target engagement, with further new assays planned for launch later this year. The multiplexing capability of MS for protein identification and quantification reports compound engagement with respect to all members of the target class in one experiment and permits compound-target engagement EC50 values to be determined for all detected DUBs.

Advertisement